Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BIOTRICITY INC.

Get SEC filing alerts via email and in your feed for BIOTRICITY INC.

BTCY

BIOTRICITY INC.

About BIOTRICITY INC.

Biotricity Inc. develops FDA-cleared remote biometric monitoring solutions focused on cardiac diagnostics and chronic disease management. Its core products include the Bioflux and Biocore Pro ECG devices and the Bioheart continuous heart monitor, serving physicians, hospitals, and diagnostic testing facilities primarily in the U.S. The company’s insourced, technology-as-a-service model integrates hardware, software, and AI-driven analytics to enhance patient care, improve diagnostic accuracy, and enable cost-effective chronic cardiac care.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from BIOTRICITY INC.

1
1
BIOTRICITY INC. Biotricity Reports 16.5% Revenue Growth to $11.75 Million, Reduces Net Loss

Via official filing (AI summary) | 4 months ago | 0 comments

2
1
BIOTRICITY INC. Biotricity Reports 20% Revenue Growth to $7.76 Million in Latest 10-Q Filing

Via official filing (AI summary) | 7 months ago | 0 comments

3
1
BIOTRICITY INC. Biotricity Reports 21% Revenue Growth and First Positive Operating Profit

Via official filing (AI summary) | 10 months ago | 0 comments

4
1
BIOTRICITY INC. Biotricity Reports $11.2 Million Net Loss, Revenue Increases 14.3% for Fiscal Year Ending March 31, 2025

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
BIOTRICITY INC. Biotricity Inc. Reports 13.5% Revenue Growth to $10.1 Million for Nine Months Ended December 31, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

6
1
BIOTRICITY INC. Biotricity Inc. Reports 13% Revenue Growth, Improved Profitability in Q2 2024

Via official filing (AI summary) | over 1 year ago | 0 comments